Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2022-01-18 Regulatory Filings
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Otrzymanie dodatkowego zlecenia na realizację usług analitycznych w zakresie kontroli jakości produktu w ramach umowy produkcyjnej z Novavax, Inc. - Content (PL)
Regulatory Filings Classification · 92% confidence The document is written in Polish and discusses a new Statement of Work (SOW#2) signed between Mabion S.A. and Novavax, Inc. This SOW relates to providing analytical services for quality control of the Nuvaxovid vaccine, building upon a previous manufacturing agreement. It details the scope (feasibility studies, method transfer, routine testing), timeline (starting Jan 2022, ending Q3 2022 for initial work, contract running 2022-2025), and business significance (expanding cooperation into analytical services). This is a specific announcement regarding a material business contract/service agreement that impacts operations and future revenue, but it is not a standard regulatory filing like a 10-K, an earnings release, or a dividend notice. It best fits the category for updates on significant business activities or contracts that don't fit other specific codes. Since it details a significant business transaction/contractual expansion, and given the available codes, it most closely aligns with a general regulatory announcement or a specific business update. Given the context of corporate filings, this type of material contract update often falls under general regulatory announcements or specific transaction reports. Since there is no specific 'Material Contract' code, and it is a formal report ('raport bieżący' context), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the contract value was the focus, but here the focus is the service expansion. RNS is the most appropriate fallback for significant, non-standard announcements.
2022-01-18 Polish
Otrzymanie dodatkowego zlecenia na produkcję banków komórkowych w ramach umowy produkcyjnej z Novavax, Inc. - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement in Polish (indicated by phrases like 'W nawiązaniu do raportów bieżących' and the content structure) regarding a new Statement of Work (SOW#3) signed under an existing Manufacturing Agreement with Novavax. It details an expansion of services (production of cell banks) and confirms the company's role as a CDMO. This type of announcement, detailing a significant operational or contractual development that is material to the business but is not a full financial report (like 10-K or IR), typically falls under general regulatory disclosures. Since it is not a specific announcement about management change (MANG), director dealing (DIRS), dividend (DIV), capital change (CAP/SHA), or a specific legal matter (LTR), the most appropriate general category for a material operational update that doesn't fit elsewhere is Regulatory Filings (RNS). The document length is short (1847 chars), but it is reporting a specific event rather than announcing the publication of a separate, larger report, thus RPA is less suitable than RNS for this type of operational update.
2022-01-14 Polish
Terminy przekazywania raportów okresowych w roku obrotowym 2022 - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text is very short (764 characters) and explicitly states the dates when the company (Mabion S.A.) will release its periodic reports (annual, quarterly, semi-annual) for the year 2022, citing Polish financial regulations (§ 80 ust. 1 Rozporządzenia Ministra Finansów). This document is not the report itself, but an announcement detailing the schedule for future report publications. According to Rule #2 (The 'Menu vs Meal' Rule), a document announcing the publication of reports fits the definition of a Report Publication Announcement (RPA).
2022-01-03 Polish
Notyfikacja 19 MAR
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving 'Krzysztof Kaczmarczyk' (Prezes Zarządu - CEO/President of the Management Board) of 'Mabion Spółka Akcyjna' concerning the acquisition ('Nabycie') of company shares ('Akcje'). Article 19 of the MAR (Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs). This perfectly matches the definition of Director's Dealing (insider trades). Therefore, the correct classification is DIRS.
2021-12-27 Polish
Powiadomienie o transakcjach na akcjach Mabion S.A. dokonanych przez osobę pełniącą obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 100% confidence The document text is very short (335 characters) and explicitly states that the Management Board received a notification from a person holding a management position (the CEO, Krzysztof Kaczmarczyk) regarding transactions made on the company's shares. It concludes by stating that the content of the notification is attached to the report. This content directly relates to insider trading or transactions by management/directors. The most specific category for this is 'Director's Dealing' (DIRS). Although it mentions an attachment, the core subject matter is the director's dealing notification itself, which is a specific regulatory disclosure type, making DIRS more appropriate than the general RPA or RNS fallback.
2021-12-27 Polish
Uzyskanie pozwolenia na prowadzenie pomostowego badania klinicznego MabionCD20 u pacjentów z reumatoidalnym zapaleniem stawów na Ukrainie - Content (PL)
Regulatory Filings Classification · 93% confidence The document is a short announcement (867 characters) from the Management Board of Mabion S.A. written in Polish. It details receiving permission from the Ministry of Health in Ukraine to conduct a clinical trial for the drug MabionCD20 for rheumatoid arthritis (RZS). This is a specific operational update regarding clinical trials and regulatory approvals in a foreign jurisdiction. It is not a full financial report (10-K, IR), an earnings release (ER), or a standard management discussion (MDA). Since it concerns a specific legal/regulatory action (obtaining a permit for a clinical trial), it fits best under Legal Proceedings Report (LTR) if interpreted broadly as a regulatory/legal matter affecting operations, or potentially Regulatory Filings (RNS) as a general announcement. Given the context of clinical trial expansion and regulatory approval, LTR (Legal Proceedings Report) is a plausible fit if the scope includes regulatory hurdles, but RNS (Regulatory Filings) is the safest fallback for specific, non-standard operational announcements that don't fit the other categories. Since it is a specific regulatory approval announcement, and not a general legal proceeding, RNS is the most appropriate general regulatory category.
2021-12-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.